Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more
COVID-19: Atnahs Continues Operations
Basildon (UK), 19 March 2020 – On 11 March 2020 the World Health Organization (WHO) declared...
More informationAtnahs Acquires Rights to Rocaltrol®, An Established Brand in Women’s Health
Basildon (UK) / Basle (Switzerland), 19 March 2020 – Atnahs (“Atnahs”), a Triton Fund V portfolio company,...
More informationAtnahs Buys Takeda Out of License Agreement for Bonviva® in Asia
Basildon (UK), 6 February 2020 – Atnahs has bought Takeda out of a license agreement for...
More informationAtnahs Acquires Rights to Established Hypertension Medicines
Basildon / Cambridge (UK), 27 January 2020 – Atnahs, a Triton Fund V portfolio company, has signed...
More informationTriton Completes Acquisition of a Majority Stake in Atnahs
Frankfurt (Germany), Basildon (United Kingdom), August 8, 2019 – Funds advised by Triton have successfully completed...
More informationAtnahs Acquires Famvir®
Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of Famvir® from...
More informationAtnahs Opens New Branch in the United Arab Emirates (UAE)
Dubai, UAE. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the opening of a new...
More informationAtnahs Acquires Remaining Stake in Pharmanovia A/S in Denmark
Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of the remaining share capital...
More informationAtnahs Launches Traxidot® (Tranexamic Acid) in the Netherlands
Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the launch of Traxidot® (Tranexamic...
More information